Bulletin
Investor Alert

Market Pulse Archives

Nov. 25, 2019, 8:34 a.m. EST

CymaBay shares fall 77% on halted trial

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    CymaBay Therapeutics Inc. (CBAY)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of CymaBay Therapeutics Inc. /zigman2/quotes/201917619/composite CBAY +3.89% are down 77% in premarket trading after the biopharmaceutical company ended two studies and halted a third for its experimental drug seladelpar. CymaBay had been testing the therapy as a treatment for non-alcoholic steatohepatitis (NASH) and in patients with primary sclerosing cholangitis and primary biliary cholangitis, both liver diseases. "We are very disappointed in having to halt the development of seladelpar at this time but patient safety and care is paramount," CEO Sujal Shah said in a news release. CymaBay stock has fallen 29% year-to-date. The S&P 500 /zigman2/quotes/210599714/realtime SPX +1.05% is up 24%.

/zigman2/quotes/201917619/composite
US : U.S.: Nasdaq
$ 3.47
+0.13 +3.89%
Volume: 1.30M
July 10, 2020 4:00p
P/E Ratio
N/A
Dividend Yield
N/A
Market Cap
$230.07 million
Rev. per Employee
N/A
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
3,185.04
+32.99 +1.05%
Volume: 2.41B
July 10, 2020 5:09p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.